Helicobacter-pylori Infektion - ein Update 2004

Literatur

• 1 Birkner B, Hotz J, Labenz J. et al . Kurzgefasste Leitlinie zum Dyspepsie-Management.  Dtsch Med Wochenschr. 2004;  129 (18) 1032-1034
• 2 Blaser M J. Hypothesis: the changing relationship of H.p. and humans: implications for health and disease.  J Infect Dis. 1999;  179 1523-1530
• 3 Brenner H, Arndt V, Stegmaier C. et al . Is H.p. infection a necessary condition for noncardia gastric cancer?.  Am J Epidemiol. 2004;  159 252-258
• 4 Chan F K, Chung S C, Suen B Y. et al . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.  N Engl J Med. 2001;  344 967-973
• 5 Chan F K, To K F, Wu J C. et al . Eradication of H.p. and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.  Lancet. 2002;  359 9-13
• 6 Chiba N, Veldhuyzen Van Zanten S JO, Escobedo S. et al . Economic evaluation of H.p. eradication in the CADET-Hp randomized controlled trial of H.p. positive primary care patients with uninvestigated dyspepsia.  Aliment Pharmacol Ther. 2004;  19 349-358
• 7 Chiba N, Veldhuyzen Van Zanten S JO, Sinclair P. et al . Treating H.p. infection in primary care patients with uninvestigated dyspepsis: the Canadian adult dyspepsia empiric treatment - H.p. positive (CADET-Hp) randomised controlled trial.  Brit Med J. 2002;  324 1-7
• 8 Churin Y, Al-Ghoul L, Kepp O. et al . Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response.  J Cell Biol. 2003;  28 (161) 249-255
• 9 Dore M P, Osato M S, Malaty H M. et al . Characterization of a culture method to recover Helicobacter pylori from the feces of infected patients.  Helicobacter. 2000;  5 165-168
• 10 El Omar E M, Rabkin C S, Gammon M D. et al . Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms.  Gastroenterology. 2003;  124 1193-201
• 11 Fischbach W, Goebeler-Kolve M E, Dragosics B. et al . Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.  Gut. 2004;  53 34-37
• 12 Gisbert J, Calvet X, Bujanda L. et al . ’Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures.  Helicobacter. 2003;  8 90-94
• 13 Glupczynski Y, Megraud F, Lopez-Brea M. et al . European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.  Eur J Clin Microbiol Infect Dis. 2001;  20 820-823
• 14 Glynn M K, Friedman C R, Gold B D. et al . Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors.  Clin Infect Dis. 2002;  35 1059-1065
• 15 Granquist A, Bredberg A, Sveger T. et al . A longitudinal cohort study on the prevalence of Helicobacter pylori antibodies in Swedish children and adolescents.  Acta Paediatr. 2002;  91 636-640
• 16 Grimm W, Fischbach W. Helicobacter pylori infection in children and juveniles: an epidemiological study on prevalence, socio-economic factors and symptoms.  Dtsch Med Wochenschr. 2003;  128 1878-1883
• 17 Heuberger F, Pantoflickowa D, Gassner M. et al . H.p. infection in Swiss adolescents. Prevalence and risk factors.  Eur J Gastroenterol Hepatol. 2003;  15 179-183
• 18 Huang J, Hunt R. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole.  Aliment Pharmacol Ther. 1999;  13 857-64
• 19 Kist M, Glocker E. Helicobacter pylori Infektionen: ResiNet - eine bundesweite Sentinelstudie zur Resistenzentwicklung.  Epidemiol Bull. 2003;  47 389-391
• 20 Klotz U, Schwab M, Treiber G. CYP2C19 Polymorphism and Proton Pump Inhibitors.  Basic Clin Pharmacol Toxicol. 2004;  95 2-8
• 21 Kuipers E J, Nelis G F, Klinkenberg-Knol E C. et al . Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.  Gut. 2004;  53 12-20
• 22 Labenz J, Blum A L, Bolten W W. et al . Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in H.p. positive patients: a randomised, double blind, placebo controlled, clinical trial.  Gut. 2002;  51 329-335
• 23 Lai K C, Lam S K, Chu K M. et al . Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.  N Engl J Med. 2002;  346 2033-2038
• 24 Leodolter A, Dominguez-Munoz J E, Von Arnim U. et al . Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting.  Am J Gastroenterol. 1999;  94 2100-2104
• 25 Leodolter A, Malfertheiner P. Aktuelle diagnostische Methoden zum Nachweis der Helicobacter-pylori-Infektion.  Dtsch Med Wochenschr. 2001;  126 207-209
• 26 Leodolter A, Wolle K, Malfertheiner P. Current standards in the diagnosis of H. pylori infection.  Dig Dis. 2001;  19 116-122
• 27 Leodolter A, Peitz U, Ebert M P. et al . Comparison of two enzyme immunoassays for the assessment of Helicobacter pylori status in stool specimens after eradication therapy.  Am J Gastroenterol. 2002;  97 1682-1686
• 28 Leodolter A, Vaira D, Bazzoli F. et al . European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test.  Aliment Pharmacol Ther. 2003;  18 927-931
• 29 Leodolter A, Wolle K, Peitz U. et al . Evaluation of a near-patient fecal antigen test for the assessment of Helicobacter pylori status.  Diagn Microbiol Infect Dis. 2004;  48 145-147
• 30 Malfertheiner P. H.p. eradication does not exacerbate gastro-oesophageal reflux disease.  Gut. 2004;  53 312-313
• 31 Malfertheiner P, Megraud F, O’Morain C. et al . Current concepts in the management of Helicobacter pylori infection - The Maastricht 2 - 2000 Consensus Report.  Aliment Pharmacol Ther. 2002;  16 167-180
• 32 Malfertheiner P, Mössner J, Fischbach W. et al . H.p. eradication is beneficial in the treatment of functional dyspepsia.  Aliment Pharmacol Ther. 2003;  15 615-625
• 33 Malfertheiner P, Peitz U, Treiber G. What constitutes failure for Helicobacter pylori eradication therapy?.  Can J Gastroenterol. 2003;  17 (Suppl B) 53B-57B
• 34 Manes G, Menchise A, De Nucci C. et al . Empirical prescribing for dyspepsia. randomised controlled trial of test and treat versus omeprazole treatment.  Brit Med J. 2003;  326 1118
• 35 Mc Coll K EL, Murray L S, Gillen D. et al . Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H.p. testing alone in the management for dyspepsia.  Brit Med J. 2002;  324 999-1002
• 36 Meining A G, Bayerdorffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients.  Eur J Gastroenterol Hepatol. 1999;  11 717-720
• 37 Melo E T, Lopes E P, Almeida J R, Albuquerque  H F, Moura I M. Seroprevalence of H. pylori antibodies in medical students and residents in Recife, Brazil.  Clin Gastroenterol. 2003;  36 134-8
• 38 Mitchell H M, Hu P, Chi Y. et al . A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation.  Gastroenterology. 1998;  114 256-261
• 39 Nardone G, Morgner A. Helicobacter pylori and gastric malignancies.  Helicobacter. 2003;  8,1 44-52
• 40 Osato M S, Reddy R, Graham D Y. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States.  Int J Antimicrob Agents. 1999;  12 341-347
• 41 Peitz U, Leodolter A, Wex T. et al . Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding.  Z Gastroenterol. 2004;  42 141-146
• 42 Raymond J, Kalach N, Bergeret M. et al . Prevalence of Helicobacter pylori infection in children according to their age. A retrospective study.  Arch Pediatr. 1998;  5 617-620
• 43 Roma-Giannikou E, Karameris A, Balatsos B. et al . Intrafamilial spread of Helicobacter pylori: a genetic analysis.  Helicobacter. 2003;  8 15-20
• 44 Rothenbacher D, Brenner H. Burden of H.p. and H.p.-related diseases in developed countries: recent developments and future implications.  Microbes Infect. 2003;  5 (8) 693-703
• 45 Schilling D, Demel A, Adamek H E. et al . A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study.  Dig Liver Dis. 2003;  35 217-221
• 46 Suerbaum S, Michetti P. Helicobacter pylori infection.  N Engl J Med. 2002;  347 1175-86
• 47 Triantafillidis J K, Gikas A, Hyphantis T. et al . Helicobacter pylori infection in hospital workers over a 5-year period. Correlation with demographic and clinical parameters.  J Gastroenterol. 2002;  37 1005-1013
• 48 Uemura N, Okamoto S, Yamamoto S. et al . H.p. infection and the development of gastric cancer.  N Engl J Med. 2001;  345 784-789
• 49 Wolle K, Leodolter A, Malfertheiner P. et al . Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000.  J Med Microbiol. 2002;  51 705-9
• 50 Wong B CY, Lam S K, Wong W M. et al . H.p. eradication to prevent gastric cancer in a high-risk region of China.  J Amer Med Assoc. 2004;  291 (2) 187-194